New Approaches in Nanomedicine for Ischemic Stroke

Correa-Paz, Clara; Silva‐Candal, Andrés da; Polo, Ester; Parcq, Jérôme; Vivien, Denis; Maysinger, Dušica; Pelaz, Beatriz; Campos, Francisco

doi:10.3390/pharmaceutics13050757

Cited by 25 publications

(17 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The penumbra area is a vulnerable, hypoperfused, and metabolically compromised brain region that can be recovered if the blood flow supply is re-established during the first few hours after a stroke. The ischemic penumbra area remains also the target of multiple protective drugs aimed to reduce or block the progression of cell death ( Castellanos et al, 2006 ; Ramos-Cabrer et al, 2011 ; Silva-Candal et al, 2017 ; Correa-Paz et al, 2021 ). After the onset of cerebral ischemia, a sequence of pathophysiological processes occurs, which are comprised of oxidative stress, inflammation, breakdown of the blood-brain barrier (BBB), calcium overload, excitotoxicity, and autophagy dysfunction ( Rodríguez-Yáñez et al, 2011 ; He et al, 2021 ) ( Figure 1 ).…”

Section: Introductionmentioning

confidence: 99%

Involvement of Ceramide Metabolism in Cerebral Ischemia

Ouro

Correa-Paz²,

Maqueda³

et al. 2022

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent neuronal death, represents one of the main causes of disability in worldwide. Although reperfusion therapies have shown efficacy in a limited number of patients with acute ischemic stroke, neuroprotective drugs and recovery strategies have been widely assessed, but none of them have been successful in clinical practice. Therefore, the search for new therapeutic approaches is still necessary. Sphingolipids consist of a family of lipidic molecules with both structural and cell signaling functions. Regulation of sphingolipid metabolism is crucial for cell fate and homeostasis in the body. Different works have emphasized the implication of its metabolism in different pathologies, such as diabetes, cancer, neurodegeneration, or atherosclerosis. Other studies have shown its implication in the risk of suffering a stroke and its progression. This review will highlight the implications of sphingolipid metabolism enzymes in acute ischemic stroke.

show abstract

Section: Introductionmentioning

confidence: 99%

Involvement of Ceramide Metabolism in Cerebral Ischemia

Ouro

Correa-Paz²,

Maqueda³

et al. 2022

Front. Mol. Biosci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…For these reasons, nanomedicine seems perfect to be used in this area to overcome these limitations and to improve the treatments efficacy. In this area, nanoparticles could be used either as contrast agents or drug carriers [90].…”

Section: Strokementioning

confidence: 99%

“…Another example is the emergence of a new micro-sized particle of the iron oxide (MPIOs) family that contains MRI contrast agents. Using MPIOs conjugated with monoclonal antibodies that targets vascular cell adhesion molecule-1 (VCAM-1) were shown to be effective in defining the "inflammatory penumbra" in ischemic stroke [90].…”

Section: Strokementioning

confidence: 99%

Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases

Mohamed

Marei

Crovella

et al. 2022

IJMS

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) are the leading causes of morbidity and mortality worldwide. However, despite the recent developments in the management of CVDs, the early and long outcomes vary considerably in patients, especially with the current challenges facing the detection and treatment of CVDs. This disparity is due to a lack of advanced diagnostic tools and targeted therapies, requiring innovative and alternative methods. Nanotechnology offers the opportunity to use nanomaterials in improving health and controlling diseases. Notably, nanotechnologies have recognized potential applicability in managing chronic diseases in the past few years, especially cancer and CVDs. Of particular interest is the use of nanoparticles as drug carriers to increase the pharmaco-efficacy and safety of conventional therapies. Different strategies have been proposed to use nanoparticles as drug carriers in CVDs; however, controversies regarding the selection of nanomaterials and nanoformulation are slowing their clinical translation. Therefore, this review focuses on nanotechnology for drug delivery and the application of nanomedicine in CVDs.

show abstract

“…In the case of cancer treatment, delivery of anticancer drugs using nanoparticles by traversing the gaps between leaky angiogenic vessels with high permeability is considered a fundamental approach to achieving selective drug delivery into tumor tissues (namely, the enhanced permeability and retention (EPR) effect) [19]. By a mechanism similar to the EPR effect, delivery of neuroprotective agents by nanoparticles into the region of ischemic stroke, as well as the benefits for cerebral I/R therapy, have been demonstrated [20,21]. In this section, we review recent reports on the use of nanoparticlebased DDS for the treatment of ischemic stroke, with a focus on the use of liposomes as drug carriers (Figure 1).…”

Section: Application Of Nanoparticle Dds For the Treatment Of Ischemi...mentioning

confidence: 99%

“…As mentioned above, the application of synthetic nanoparticles for the design of therapeutic systems is suggested to offer a promising treatment approach for ischemic stroke. While we reviewed only a few examples of the use of PLGA-nanoparticles and PAMAM dendrimers, several review articles have also highlighted the utility of a variety of other synthetic nanoparticle-based DDS [21,62,63].…”

Section: Application Of Other Nanoparticle Ddsmentioning

confidence: 99%

Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke

2022

View full text Add to dashboard Cite

Ischemic stroke is still one of the leading causes of high mortality and severe disability worldwide. Therapeutic options for ischemic stroke and subsequent cerebral ischemia/reperfusion injury remain limited due to challenges associated with drug permeability through the blood-brain barrier (BBB). Neuroprotectant delivery with nanoparticles, including liposomes, offers a promising solution to address this problem, as BBB disruption following ischemic stroke allows nanoparticles to pass through the intercellular gaps between endothelial cells. To ameliorate ischemic brain damage, a number of nanotherapeutics encapsulating neuroprotective agents, as well as surface-modified nanoparticles with specific ligands targeting the injured brain regions, have been developed. Combination therapy with nanoparticles encapsulating neuroprotectants and tissue plasminogen activator (t-PA), a globally approved thrombolytic agent, has been demonstrated to extend the narrow therapeutic time window of t-PA. In addition, the design of biomimetic drug delivery systems (DDS) employing circulating cells (e.g., leukocytes, platelets) with unique properties has recently been investigated to overcome the injured BBB, utilizing these cells’ inherent capability to penetrate the ischemic brain. Herein, we review recent findings on the application and utility of nanoparticle DDS, particularly liposomes, and various approaches to developing biomimetic DDS functionalized with cellular membranes/membrane proteins for the treatment of ischemic stroke.

show abstract

New Approaches in Nanomedicine for Ischemic Stroke

Cited by 25 publications

References 111 publications

Involvement of Ceramide Metabolism in Cerebral Ischemia

Involvement of Ceramide Metabolism in Cerebral Ischemia

Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases

Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke

Contact Info

Product

Resources

About